Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Andrews

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A proteaseMartin J Slater, David M Andrews, Graham Baker, et al.
Organic Letters|November 25, 2003
Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A proteaseMartin J Slater, Elizabeth M Amphlett, David M Andrews, et al.
Chemical Science|June 24, 2021
Query-guided protein-protein interaction inhibitor discoverySergio Celis, Fruzsina Hobor, Thomas James, et al.
European Journal of Medicinal Chemistry|May 17, 2003
The design of potent, non-peptidic inhibitors of hepatitis C proteaseDavid M Andrews, Helene M Chaignot, Barry A Coomber, et al.
Organic Letters|November 25, 2003
Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A proteaseDavid M Andrews, Michael C Barnes, Mike D Dowle, et al.
Journal of Medicinal Chemistry|May 23, 2012
Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinaseRichard A Norman, Anne-Kathrin Schott, David M Andrews, et al.
Journal of Medicinal Chemistry|July 18, 2017
Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of ProteinsNiall Igoe, Elliott D Bayle, Cynthia Tallant, et al.
Journal of Medicinal Chemistry|January 10, 2017
Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo StudiesNiall Igoe, Elliott D Bayle, Oleg Fedorov, et al.
Bioorganic & Medicinal Chemistry Letters|July 12, 2008
Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding modeM Raymond V Finlay, David G Acton, David M Andrews, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancerRobert H Bradbury, Neil J Hales, Alfred A Rabow, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A proteaseMartin J Slater, David M Andrews, Graham Baker, et al.
Organic Letters|November 25, 2003
Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A proteaseMartin J Slater, Elizabeth M Amphlett, David M Andrews, et al.
Chemical Science|June 24, 2021
Query-guided protein-protein interaction inhibitor discoverySergio Celis, Fruzsina Hobor, Thomas James, et al.
European Journal of Medicinal Chemistry|May 17, 2003
The design of potent, non-peptidic inhibitors of hepatitis C proteaseDavid M Andrews, Helene M Chaignot, Barry A Coomber, et al.
Organic Letters|November 25, 2003
Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A proteaseDavid M Andrews, Michael C Barnes, Mike D Dowle, et al.
Journal of Medicinal Chemistry|May 23, 2012
Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinaseRichard A Norman, Anne-Kathrin Schott, David M Andrews, et al.
Journal of Medicinal Chemistry|July 18, 2017
Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of ProteinsNiall Igoe, Elliott D Bayle, Cynthia Tallant, et al.
Journal of Medicinal Chemistry|January 10, 2017
Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo StudiesNiall Igoe, Elliott D Bayle, Oleg Fedorov, et al.
Bioorganic & Medicinal Chemistry Letters|July 12, 2008
Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding modeM Raymond V Finlay, David G Acton, David M Andrews, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancerRobert H Bradbury, Neil J Hales, Alfred A Rabow, et al.
Pageof 11